Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04736706




Registration number
NCT04736706
Ethics application status
Date submitted
29/01/2021
Date registered
3/02/2021
Date last updated
12/03/2024

Titles & IDs
Public title
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Scientific title
An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Secondary ID [1] 0 0
MK-6482-012
Secondary ID [2] 0 0
6482-012
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Carcinoma, Renal Cell 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Pembrolizumab
Treatment: Drugs - Belzutifan
Treatment: Other - Pembrolizumab/Quavonlimab
Treatment: Drugs - Lenvatinib

Experimental: Pembrolizumab + Belzutifan + Lenvatinib - Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 18 administrations (up to \~2 years). Belzutifan and lenvatinib will be administered orally once daily (QD) until progressive disease or discontinuation.

Experimental: Pembrolizumab/Quavonlimab + Lenvatinib - Participants will receive pembrolizumab/quavonlimab (co-formulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS lenvatinib 20 mg. Pembrolizumab/quavonlimab will be administered IV Q6W for up to 18 administrations (up to \~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.

Active comparator: Pembrolizumab + Lenvatinib - Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 18 administrations (up to \~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.


Treatment: Other: Pembrolizumab
Pembrolizumab 400 mg administered Q6W via IV infusion

Treatment: Drugs: Belzutifan
Belzutifan 120 mg administered QD via oral tablet

Treatment: Other: Pembrolizumab/Quavonlimab
Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion

Treatment: Drugs: Lenvatinib
Lenvatinib 20 mg administered QD via oral capsule
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Timepoint [1] 0 0
Up to approximately 46 months
Primary outcome [2] 0 0
Overall Survival (OS)
Timepoint [2] 0 0
Up to approximately 66 months
Secondary outcome [1] 0 0
Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR
Timepoint [1] 0 0
Up to approximately 46 months
Secondary outcome [2] 0 0
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR
Timepoint [2] 0 0
Up to approximately 66 months
Secondary outcome [3] 0 0
Number of Participants Who Experienced At least One Adverse Event (AE)
Timepoint [3] 0 0
Up to approximately 66 months
Secondary outcome [4] 0 0
Number of Participants Who Discontinue Study Treatment Due to an AE
Timepoint [4] 0 0
Up to approximately 66 months

Eligibility
Key inclusion criteria
* Has histologically confirmed diagnosis of RCC with clear cell component.
* Has received no prior systemic therapy for advanced ccRCC
* Male participants are abstinent from heterosexual intercourse or agree to use contraception during and for at least 7 days after last dose of study intervention with belzutifan and lenvatinib.
* Female participants are not pregnant or breastfeeding and are either not a woman of child-bearing potential (WOCBP) or use a contraceptive method that is highly effective or are abstinent from heterosexual intercourse during the intervention period and for at least 120 days after pembrolizumab or pembrolizumab/quavonlimab or for at least 30 days after last dose of lenvatinib or belzutifan, whichever occurs last
* Has adequately controlled blood pressure with or without antihypertensive medications
* Has adequate organ function.
* Participants receiving bone resorptive therapy must have therapy initiated at least 2 weeks prior to randomization/allocation
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
* Has had major surgery, other than nephrectomy within 4 weeks prior to randomization
* Has known central nervous system (CNS) metastases and/or carcinomatous meningitis
* Has received prior radiotherapy within 2 weeks prior to first dose of study intervention
* Has hypoxia or requires intermittent supplemental oxygen or requires chronic supplemental oxygen
* Has clinically significant cardiac disease within 12 months from first dose of study intervention
* Has a history of interstitial lung disease
* Has symptomatic pleural effusion; a participant who is clinically stable following treatment of this condition is eligible
* Has preexisting gastrointestinal or non-gastrointestinal fistula
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment
* Has a known psychiatric or substance abuse disorder that would interfere with requirements of the study
* Has received a live or live-attenuated vaccine within 30 days before the first dose of study drug; killed vaccines are allowed
* Has an active autoimmune disease that has required systemic treatment in the past 2 years
* Has a history of noninfectious pneumonitis that required steroids or has current pneumonitis
* Has an active infection requiring systemic therapy
* Has a known history of human immunodeficiency virus (HIV) infection
* Has a known history of Hepatitis B
* Has radiographic evidence of intratumoral cavitation, encasement or invasion of a major blood vessel
* Has clinically significant history of bleeding within 3 months prior to randomization
* Has had an allogenic tissue/solid organ transplant

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/04/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
29/10/2026
Actual
Sample size
Target
1653
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Recruitment hospital [1] 0 0
Liverpool Hospital ( Site 4006) - Liverpool
Recruitment hospital [2] 0 0
Macquarie University ( Site 4007) - Macquarie University
Recruitment hospital [3] 0 0
Lyell McEwin Hospital ( Site 4004) - Elizabeth Vale
Recruitment hospital [4] 0 0
Monash Health ( Site 4008) - Clayton
Recruitment hospital [5] 0 0
Fiona Stanley Hospital ( Site 4009) - Murdock
Recruitment postcode(s) [1] 0 0
2170 - Liverpool
Recruitment postcode(s) [2] 0 0
2109 - Macquarie University
Recruitment postcode(s) [3] 0 0
5112 - Elizabeth Vale
Recruitment postcode(s) [4] 0 0
3168 - Clayton
Recruitment postcode(s) [5] 0 0
6150 - Murdock
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Maine
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Minnesota
Country [14] 0 0
United States of America
State/province [14] 0 0
Mississippi
Country [15] 0 0
United States of America
State/province [15] 0 0
New Hampshire
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
Oregon
Country [18] 0 0
United States of America
State/province [18] 0 0
South Carolina
Country [19] 0 0
United States of America
State/province [19] 0 0
Tennessee
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Washington
Country [22] 0 0
Brazil
State/province [22] 0 0
Ceara
Country [23] 0 0
Brazil
State/province [23] 0 0
Espirito Santo
Country [24] 0 0
Brazil
State/province [24] 0 0
Minas Gerais
Country [25] 0 0
Brazil
State/province [25] 0 0
Rio Grande Do Norte
Country [26] 0 0
Brazil
State/province [26] 0 0
Rio Grande Do Sul
Country [27] 0 0
Brazil
State/province [27] 0 0
Sao Paulo
Country [28] 0 0
Canada
State/province [28] 0 0
Alberta
Country [29] 0 0
Canada
State/province [29] 0 0
British Columbia
Country [30] 0 0
Canada
State/province [30] 0 0
Ontario
Country [31] 0 0
Canada
State/province [31] 0 0
Quebec
Country [32] 0 0
Chile
State/province [32] 0 0
Araucania
Country [33] 0 0
Chile
State/province [33] 0 0
Coquimbo
Country [34] 0 0
Chile
State/province [34] 0 0
Lbtdr Gen Bernardo O Higgins
Country [35] 0 0
Chile
State/province [35] 0 0
Region M. De Santiago
Country [36] 0 0
China
State/province [36] 0 0
Anhui
Country [37] 0 0
China
State/province [37] 0 0
Beijing
Country [38] 0 0
China
State/province [38] 0 0
Chongqing
Country [39] 0 0
China
State/province [39] 0 0
Fujian
Country [40] 0 0
China
State/province [40] 0 0
Guangdong
Country [41] 0 0
China
State/province [41] 0 0
Heilongjiang
Country [42] 0 0
China
State/province [42] 0 0
Henan
Country [43] 0 0
China
State/province [43] 0 0
Hubei
Country [44] 0 0
China
State/province [44] 0 0
Hunan
Country [45] 0 0
China
State/province [45] 0 0
Jiangsu
Country [46] 0 0
China
State/province [46] 0 0
Jiangxi
Country [47] 0 0
China
State/province [47] 0 0
Shaanxi
Country [48] 0 0
China
State/province [48] 0 0
Shanghai
Country [49] 0 0
China
State/province [49] 0 0
Sichuan
Country [50] 0 0
China
State/province [50] 0 0
Tianjin
Country [51] 0 0
China
State/province [51] 0 0
Zhejiang
Country [52] 0 0
Colombia
State/province [52] 0 0
Antioquia
Country [53] 0 0
Colombia
State/province [53] 0 0
Atlantico
Country [54] 0 0
Colombia
State/province [54] 0 0
Cesar
Country [55] 0 0
Colombia
State/province [55] 0 0
Distrito Capital De Bogota
Country [56] 0 0
Colombia
State/province [56] 0 0
Risaralda
Country [57] 0 0
Colombia
State/province [57] 0 0
Santander
Country [58] 0 0
Croatia
State/province [58] 0 0
Grad Zagreb
Country [59] 0 0
Croatia
State/province [59] 0 0
Splitsko-dalmatinska Zupanija
Country [60] 0 0
Croatia
State/province [60] 0 0
Zagrebacka Zupanija
Country [61] 0 0
Czechia
State/province [61] 0 0
Brno-mesto
Country [62] 0 0
Czechia
State/province [62] 0 0
Jihomoravsky Kraj
Country [63] 0 0
Czechia
State/province [63] 0 0
Moravskoslezsky Kraj
Country [64] 0 0
Czechia
State/province [64] 0 0
Olomouc
Country [65] 0 0
Czechia
State/province [65] 0 0
Praha 4
Country [66] 0 0
Czechia
State/province [66] 0 0
Praha 5
Country [67] 0 0
Denmark
State/province [67] 0 0
Hovedstaden
Country [68] 0 0
Denmark
State/province [68] 0 0
Syddanmark
Country [69] 0 0
Finland
State/province [69] 0 0
Pirkanmaa
Country [70] 0 0
Finland
State/province [70] 0 0
Pohjois-Savo
Country [71] 0 0
Finland
State/province [71] 0 0
Uusimaa
Country [72] 0 0
Finland
State/province [72] 0 0
Varsinais-Suomi
Country [73] 0 0
France
State/province [73] 0 0
Bouches-du-Rhone
Country [74] 0 0
France
State/province [74] 0 0
Doubs
Country [75] 0 0
France
State/province [75] 0 0
Haute-Garonne
Country [76] 0 0
France
State/province [76] 0 0
Haute-Vienne
Country [77] 0 0
France
State/province [77] 0 0
Maine-et-Loire
Country [78] 0 0
France
State/province [78] 0 0
Nord-Pas-de-Calais
Country [79] 0 0
France
State/province [79] 0 0
Rhone
Country [80] 0 0
France
State/province [80] 0 0
Val-de-Marne
Country [81] 0 0
France
State/province [81] 0 0
Paris
Country [82] 0 0
Germany
State/province [82] 0 0
Baden-Wurttemberg
Country [83] 0 0
Germany
State/province [83] 0 0
Mecklenburg-Vorpommern
Country [84] 0 0
Germany
State/province [84] 0 0
Berlin
Country [85] 0 0
Guatemala
State/province [85] 0 0
Quetzaltenango
Country [86] 0 0
Guatemala
State/province [86] 0 0
Guatemala
Country [87] 0 0
Hungary
State/province [87] 0 0
Bacs-Kiskun
Country [88] 0 0
Hungary
State/province [88] 0 0
Bekes
Country [89] 0 0
Hungary
State/province [89] 0 0
Jasz-Nagykun-Szolnok
Country [90] 0 0
Hungary
State/province [90] 0 0
Vas
Country [91] 0 0
Hungary
State/province [91] 0 0
Budapest
Country [92] 0 0
Hungary
State/province [92] 0 0
Debrecen
Country [93] 0 0
Ireland
State/province [93] 0 0
Dublin
Country [94] 0 0
Italy
State/province [94] 0 0
Emilia-Romagna
Country [95] 0 0
Italy
State/province [95] 0 0
Lombardia
Country [96] 0 0
Italy
State/province [96] 0 0
Roma
Country [97] 0 0
Italy
State/province [97] 0 0
Bari
Country [98] 0 0
Italy
State/province [98] 0 0
Milano
Country [99] 0 0
Italy
State/province [99] 0 0
Napoli
Country [100] 0 0
Italy
State/province [100] 0 0
Terni
Country [101] 0 0
Japan
State/province [101] 0 0
Aichi
Country [102] 0 0
Japan
State/province [102] 0 0
Chiba
Country [103] 0 0
Japan
State/province [103] 0 0
Ehime
Country [104] 0 0
Japan
State/province [104] 0 0
Hokkaido
Country [105] 0 0
Japan
State/province [105] 0 0
Kanagawa
Country [106] 0 0
Japan
State/province [106] 0 0
Nara
Country [107] 0 0
Japan
State/province [107] 0 0
Osaka
Country [108] 0 0
Japan
State/province [108] 0 0
Saitama
Country [109] 0 0
Japan
State/province [109] 0 0
Shizuoka
Country [110] 0 0
Japan
State/province [110] 0 0
Tokyo
Country [111] 0 0
Japan
State/province [111] 0 0
Toyama
Country [112] 0 0
Japan
State/province [112] 0 0
Fukuoka
Country [113] 0 0
Japan
State/province [113] 0 0
Kumamoto
Country [114] 0 0
Japan
State/province [114] 0 0
Niigata
Country [115] 0 0
Japan
State/province [115] 0 0
Okayama
Country [116] 0 0
Japan
State/province [116] 0 0
Tokushima
Country [117] 0 0
Korea, Republic of
State/province [117] 0 0
Kyonggi-do
Country [118] 0 0
Korea, Republic of
State/province [118] 0 0
Taejon-Kwangyokshi
Country [119] 0 0
Korea, Republic of
State/province [119] 0 0
Seoul
Country [120] 0 0
Malaysia
State/province [120] 0 0
Johor
Country [121] 0 0
Malaysia
State/province [121] 0 0
Wilayah Persekutuan Putrajaya
Country [122] 0 0
Malaysia
State/province [122] 0 0
Kuala Lumpur
Country [123] 0 0
Mexico
State/province [123] 0 0
Jalisco
Country [124] 0 0
Mexico
State/province [124] 0 0
Nuevo Leon
Country [125] 0 0
Mexico
State/province [125] 0 0
Queretaro
Country [126] 0 0
Mexico
State/province [126] 0 0
Cdmx
Country [127] 0 0
Mexico
State/province [127] 0 0
Oaxaca
Country [128] 0 0
Norway
State/province [128] 0 0
Akershus
Country [129] 0 0
Norway
State/province [129] 0 0
Aust-Agder
Country [130] 0 0
Norway
State/province [130] 0 0
Hordaland
Country [131] 0 0
Norway
State/province [131] 0 0
Ostfold
Country [132] 0 0
Norway
State/province [132] 0 0
Sor-Trondelag
Country [133] 0 0
Norway
State/province [133] 0 0
Oslo
Country [134] 0 0
Philippines
State/province [134] 0 0
National Capital Region
Country [135] 0 0
Poland
State/province [135] 0 0
Kujawsko-pomorskie
Country [136] 0 0
Poland
State/province [136] 0 0
Mazowieckie
Country [137] 0 0
Poland
State/province [137] 0 0
Wielkopolskie
Country [138] 0 0
Poland
State/province [138] 0 0
Zachodniopomorskie
Country [139] 0 0
Romania
State/province [139] 0 0
Alba
Country [140] 0 0
Romania
State/province [140] 0 0
Dolj
Country [141] 0 0
Romania
State/province [141] 0 0
Timis
Country [142] 0 0
Romania
State/province [142] 0 0
Bucuresti
Country [143] 0 0
Russian Federation
State/province [143] 0 0
Altayskiy Kray
Country [144] 0 0
Russian Federation
State/province [144] 0 0
Ivanovskaya Oblast
Country [145] 0 0
Russian Federation
State/province [145] 0 0
Krasnoyarskiy Kray
Country [146] 0 0
Russian Federation
State/province [146] 0 0
Moskva
Country [147] 0 0
Russian Federation
State/province [147] 0 0
Nizhegorodskaya Oblast
Country [148] 0 0
Russian Federation
State/province [148] 0 0
Sankt-Peterburg
Country [149] 0 0
Serbia
State/province [149] 0 0
Beograd
Country [150] 0 0
Serbia
State/province [150] 0 0
Nisavski Okrug
Country [151] 0 0
Serbia
State/province [151] 0 0
Sremski Okrug
Country [152] 0 0
South Africa
State/province [152] 0 0
Eastern Cape
Country [153] 0 0
South Africa
State/province [153] 0 0
Gauteng
Country [154] 0 0
South Africa
State/province [154] 0 0
Western Cape
Country [155] 0 0
Spain
State/province [155] 0 0
Barcelona
Country [156] 0 0
Spain
State/province [156] 0 0
Cantabria
Country [157] 0 0
Spain
State/province [157] 0 0
Gerona
Country [158] 0 0
Spain
State/province [158] 0 0
Madrid
Country [159] 0 0
Spain
State/province [159] 0 0
Malaga
Country [160] 0 0
Sweden
State/province [160] 0 0
Jonkopings Lan
Country [161] 0 0
Sweden
State/province [161] 0 0
Stockholms Lan
Country [162] 0 0
Sweden
State/province [162] 0 0
Uppsala Lan
Country [163] 0 0
Sweden
State/province [163] 0 0
Vasterbottens Lan
Country [164] 0 0
Sweden
State/province [164] 0 0
Vastra Gotalands Lan
Country [165] 0 0
Taiwan
State/province [165] 0 0
Kaohsiung
Country [166] 0 0
Taiwan
State/province [166] 0 0
Taichung
Country [167] 0 0
Taiwan
State/province [167] 0 0
Tainan
Country [168] 0 0
Taiwan
State/province [168] 0 0
Taipei
Country [169] 0 0
Taiwan
State/province [169] 0 0
Taoyuan
Country [170] 0 0
Thailand
State/province [170] 0 0
Krung Thep Maha Nakhon
Country [171] 0 0
Turkey
State/province [171] 0 0
Ankara
Country [172] 0 0
Turkey
State/province [172] 0 0
Edirne
Country [173] 0 0
Turkey
State/province [173] 0 0
Istanbul
Country [174] 0 0
Turkey
State/province [174] 0 0
Izmir
Country [175] 0 0
Ukraine
State/province [175] 0 0
Cherkaska Oblast
Country [176] 0 0
Ukraine
State/province [176] 0 0
Chernihivska Oblast
Country [177] 0 0
Ukraine
State/province [177] 0 0
Dnipropetrovska Oblast
Country [178] 0 0
Ukraine
State/province [178] 0 0
Ivano-Frankivska Oblast
Country [179] 0 0
Ukraine
State/province [179] 0 0
Kharkivska Oblast
Country [180] 0 0
Ukraine
State/province [180] 0 0
Kyivska Oblast
Country [181] 0 0
Ukraine
State/province [181] 0 0
Lvivska Oblast
Country [182] 0 0
United Kingdom
State/province [182] 0 0
Cambridgeshire
Country [183] 0 0
United Kingdom
State/province [183] 0 0
England
Country [184] 0 0
United Kingdom
State/province [184] 0 0
London, City Of

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Merck Sharp & Dohme LLC
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Eisai Inc.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC).

The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.
Trial website
https://clinicaltrials.gov/study/NCT04736706
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Merck Sharp & Dohme LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04736706